Home>Topics>Stocks>Idenix Pharmaceuticals

Idenix Pharmaceuticals IDIX

  1. All
  2. Commentary
  3. Headlines
    1. A Pre-Earnings Update On Gilead

      Headlines

      Thu, 10 Jul 2014

      By DoctoRx : Background : Gilead Sciences ( GILD ) may remain substantially undervalued relative to the market despite its tremendous stock price appreciation recently and over many years. The following shows GILD versus the S&P 500 and the NASDAQ since this Yahoo! Finance chart begins with ...

    2. What If Legacy Pharmaceutical And Consumer Business Keeps Falling For Merck?

      Headlines

      Fri, 27 Jun 2014

      By Trefis : Merck's ( MRK ) legacy pharmaceuticals and consumer business constitutes roughly 30% of the company's value according to our estimates. Despite it being a segment that has seen a revenue decline in recent years, its value contribution remains high due to much higher sales compared to ...

    3. Mast Therapeutics' MST-188 Would Fit Well In Merck's Drug Development Pipeline

      Headlines

      Tue, 24 Jun 2014

      MRK ) is another company that has conducted some recent M&A activity, with its proposed acquisition of Idenix Pharmaceuticals , Inc. for $3.85 billion . Merck is hoping this acquisition provides it with a serious hepatitis C contender

    4. Keryx Biopharmaceuticals: Baupost Group's New Position Suggests A Possible Takeout And 100%+ Gains

      Headlines

      Tue, 24 Jun 2014

      good chance that this could happen with Keryx Biopharmaceuticals ( KERX ). The reason is because Baupost Group, of Idenix ( IDIX ) fame, has recently acquired an over 10% stake in KERX and has become its largest shareholder. As explained by Market Realist

    5. Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms

      Headlines

      Fri, 20 Jun 2014

      By Austrolib: Merck's ( MRK ) acquisition of Idenix ( IDIX ) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have

    6. Merck begins tender offer for Idenix

      Headlines

      Fri, 20 Jun 2014

      Merck ( MRK ) begins the process of acquiring Idenix Pharmaceuticals ( IDIX ) for $24.50 in cash. It will file a Schedule ..... 14D-9 that includes the recommendation of the IDIX BOD that shareholders accept MRK's offer. Post

    7. Why This Physician Is Bullish On Celgene

      Headlines

      Thu, 19 Jun 2014

      takeover activity. Monday, Merck ( MRK ) announced that it is going to acquire the development-stage biopharma company Idenix ( IDIX ) for nearly $4 B. Actavis ( ACT ) is acquiring fallen angel Forest Labs ( FRX ) at a high valuation. Amongst the giants

    8. Hepatitis C May Give A Big Boost To These Drug Stocks - If The FDA Approves

      Headlines

      Tue, 17 Jun 2014

      billion in sales for its new $1000 hepatitis C pill, Solvadi. It's also why Merck ( MRK ) acquired Idenix Pharmaceuticals Inc. ( IDIX ) earlier this month. The list of companies developing hepatitis C medication includes the aforementioned

    9. Merck shareholder tries to scuttle the Idenix deal

      Headlines

      Mon, 16 Jun 2014

      Ronald Burns files suit (Burns vs Idenix Pharmaceuticals ) attempting to block its $3.9B acquisition of Idenix ( IDIX +1.4% ) stating that the price undervalues IDIX . He cites IDIX 's intrinsic value and a flawed

    10. Buyout Cycle Boosts Biotech ETFs

      Headlines

      Fri, 13 Jun 2014

      Fabian : The recent buyout of Idenix Pharmaceuticals ( IDIX ) by drug maker Merck & Co ..... 230% single-day gain that IDIX experienced as a result of the ..... modified equal-weighted index, IDIX had a much larger impact on the

    « Prev12345Next »
    Content Partners